iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 2,500 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $90.94, for a total transaction of $227,350.00. Following the completion of the sale, the chief executive officer owned 2,202,500 shares of the company’s stock, valued at $200,295,350. This trade represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

IRMD stock traded up $0.96 during trading on Wednesday, reaching $90.14. The company had a trading volume of 62,414 shares, compared to its average volume of 80,609. The firm has a 50-day simple moving average of $98.63 and a 200-day simple moving average of $93.51. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 51.51 and a beta of 1.11. iRadimed Corporation has a twelve month low of $50.00 and a twelve month high of $107.90.

iRadimed (NASDAQ:IRMD) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Sell-side analysts expect that iRadimed Corporation will post 1.94 earnings per share for the current year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were paid a $0.20 dividend. This is a boost from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is 45.71%.

Institutional Trading of iRadimed

Several institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC lifted its stake in iRadimed by 4.5% during the 1st quarter. SG Americas Securities LLC now owns 73,561 shares of the medical equipment provider’s stock valued at $7,081,000 after acquiring an additional 3,170 shares during the period. Hsbc Holdings PLC lifted its stake in iRadimed by 19.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock valued at $2,103,000 after acquiring an additional 3,468 shares during the period. Aristides Capital LLC lifted its stake in iRadimed by 5.0% during the 4th quarter. Aristides Capital LLC now owns 27,734 shares of the medical equipment provider’s stock valued at $2,698,000 after acquiring an additional 1,309 shares during the period. T. Rowe Price Investment Management Inc. lifted its stake in iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after acquiring an additional 205,783 shares during the period. Finally, Invesco Ltd. lifted its stake in iRadimed by 473.9% during the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after acquiring an additional 29,010 shares during the period. 92.34% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Lake Street Capital reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm reiterated a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $120.00.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.